“Bimekizumab 4-Year Maintenance of Responses in Week 16 Responders With Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-Label Extension Phase 3 Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s437. Accessed October 19, 2025. https://skin.dermsquared.com/skin/article/view/3114.